


### **OVERVIEW**

Alzheimer's disease is the only top 10 cause of death in the United States with no treatment or means of prevention, yet federal research funding is a fraction of that for other major diseases. Approximately 5.5 million Americans are living with Alzheimer's, and by 2050, that number could rise as high as 16 million. The United States currently has 16 million family caregivers which provided an estimated 18.2 billion hours of unpaid care in 2016. Total annual out-of-pocket payments in the U.S. for healthcare, long-term care, and hospice care for people with Alzheimer's and other dementias is projected to total \$259 billion in 2017 and increase to \$1.1 trillion by 2050 if we don't have a treatment or cure. Worldwide about 50 million people have some form of dementia, and someone in the world develops dementia every three seconds.

UsAgainstAlzheimer's is driven by passion and purpose and is powered by individuals living with dementia and their care partners. We forge innovative and comprehensive solutions to Alzheimer's. We press for greater urgency and collaboration from government, industry and the scientific community in the quest for an Alzheimer's cure. We act on those beliefs through strategic and disruptive investments in infrastructure, big data, and national and global convening platforms. And we mobilize communities most deeply affected by the disease, including women, African Americans, Latinos, caregivers, veterans, youth, activists, the faith community and researchers.

#### TO ACHIEVE THE AUDACIOUS BUT ATTAINABLE GOAL OF STOPPING ALZHEIMER'S, WE MUST:

- ACCELERATE AND MULTIPLY Research in Lifesaving Treatments and a Cure, and Change the Path of Diagnosis
- INCREASE Public and Private Sector Investment in Stopping Alzheimer's Disease
- AMPLIFY the Voices and Meet the Dire Needs of Alzheimer's Patients, Caregivers and Families



### **OUR ACHIEVEMENTS**

### Since its founding in 2010, UsAgainstAlzheimer's has worked collaboratively to:

- 1. Establish a national goal of preventing and treating Alzheimer's by 2025;
- 2. Drive global efforts to embrace and achieve a similar 2025 goal;
- 3. Secure more than \$500 million in additional public funding for Alzheimer's research;
- 4. Forge industry and regulatory commitments to improve efficiencies in expedited drug discovery and to assure clarity in approval processes needed for innovative medicines to reach those in need:
- 5. Create a nationwide, grassroots coalition of more than 90 organizations and corporations touching well more than 3 million individuals.

### Working with congressional and federal policymakers and stakeholders, we have accomplished many milestone successes, including:

Establishing a national goal of preventing and effectively treating Alzheimer's by 2025 through the National Alzheimer's Plan.

Driving global efforts that resulted in leaders of the world's most powerful nations, the G7 group, embracing a similar 2025 goal and calling for greater levels of research investment and collaboration.

Helping drive U.S. investment in dementia research at the National Institutes of Health from \$448 million in 2010 to \$1.8 billion for FY 2018 (a more than four-fold increase) and prompting the U.K., Canada and Japan to commit to greater research investment.

Helping to develop and introduce Congressional legislation including the CHANGE Act, the EUREKA Act, the Alzheimer's Beneficiary and Caregiver Support Act and the 21st Century Cares Act.

Successfully engaging with the FDA to release revised guidance which recognizes the value of patient engagement in clinical trials and highlights the value of data sharing.

### **NETWORKS**

We work through collaboration, mobilizing the most deeply affected communities and forging important partnerships. United under the relentless force of UsAgainstAlzheimer's, our eight networks are dedicated to stopping the disease and caring for those touched by it.

# Activists Against Alzheimer's

Activists Against Alzheimer's builds on the energies of the highly motivated Alzheimer's community efforts to fight this disease. Our membership represents caregivers nationwide. With a moderated online caregiver support group and active digital outreach, the Network reaches 3 million people.

## African Americans Against Alzheimer's

AfricanAmericansAgainstAlzheimer's is the preeminent voice in and for the African-American community on Alzheimer's and its disproportionate impact on African Americans. With the play Forget Me Not, it reaches communities nationwide to build appreciation for and participation in clinical trials by African Americans.

# ClergyAgainst Alzheimer's

ClergyAgainstAlzheimer's is a diverse, multi-faith network of ordained clergy working to focus our nation's attention on Alzheimer's and related dementias. The Network promotes dignity, compassionate care and quality of life for individuals with friends and caregivers.

# Latinos Against Alzheimer's

Latinos Against Alzheimer's marshals resources and action to address the growing impact of Alzheimer's and dementia on our nation's 55 million Latino families. Through a network of cross-sector stakeholders, the network spearheads strategic convening and coalition building, legislative advocacy, and culturally tailored education and brain health promotion efforts across the country.

### Researchers Against Alzheimer's

Researchers Against Alzheimer's is a global network of top Alzheimer's disease researchers that informs policymakers here and abroad on the importance of increasing public research funding and instituting reforms (such as accelerating drug pipeline) to meet the national goal of ending Alzheimer's by 2025.

# Veterans **Against**Alzheimer's

VeteransAgainstAlzheimer's is taking action to support our brave veterans and their families affected by Alzheimer's by raising awareness and calling for improved access to quality care and increased research for a cure.

# WomenAgainst Alzheimer's

WomenAgainstAlzheimer's brings Alzheimer's out of the shadows as women's health and financial crisis, given its heavy impact on women as patients and caregivers. Through a national network of influential women, the Network presses federal policymakers for legislative and funding opportunities for gender-specific research.

### **CONVENED COALITIONS & SIGNATURE CAMPAIGNS**





### FaithUnited4gainstAlzheimer's

# Latinos Against Alzheimer's Coalition

Convened by the UsAgainstAlzheimer's Network





UsAgainstAlzheimer's co-convenes this growing national coalition of more than 90 diverse organizations that work collaboratively to related disorders and to accelerate transformational progress in care and support, detection and diagnosis, and research leading to prevention, effective treatment and eventual cure.

UsAgainstAlzheimer's convenes this coalition – a leading voice in the global fight against Alzheimer's, with 15 corporate members, and partnerships globally with public authorities.

Faith United Against Alzheimer's is a diverse coalition of faith leaders and organizations working to mobilize the faith community in the fight against Alzheimer's disease and related dementias.

The LatinosAgainstAlzheimer's Coalition is the first-ever coalition of Latino-serving organizations coordinating Alzheimer's awareness and brain health promotion efforts in the Latino community.

The Youth Against Alzheimer's Coalition (YAAC) positions Alzheimer's as an urgent economic and public health issue impacting families across generations, mobilizing young people and youth-serving organizations through storytelling, advocacy, and strategic convening.

The We Won't Wait Campaign is a the first-ever effort to define Alzheimer's as both an economic as well as a health-related injustice against women, and it is the organization's next phase in its successful work over the last four years fighting for a cure through a woman's lens.

### **INCUBATED INITIATIVES**



GAP is establishing a standing global trial-ready platform to drive seeking to reduce clinical testing cycles by two years or more and to achieve more uniformity in trial populations by building large, well-characterized clinical trial sites and an adaptive proof-of-concept trial mechanism.



AD PACE a first-of-its kind initiative led by patients, caregivers, and other advocates in collaboration with drug and device developers, regulatory and payer authorities, and researchers. We will build a platform to share patient and caregiver preferences with those who are developing new therapies and seeking to assure access to treatment, care and services that change the lives of those affected by Alzheimer's.